Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy: Potential for treatment utilization

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Bamias, Aristotelis ^a   Gavalas, Nikos G ^a   Karadimou, Alexandra ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; MATUZUMAB; OREGOVOMAB; PACLITAXEL; PERTUZUMAB; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; MONOCLONAL ANTIBODY;

CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL MOTILITY; FEMALE; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; LYMPHOCYTE FUNCTION; MELANOMA; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REVIEW; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; OVARY TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 79953284963     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/791603     Document Type: Review

References (173)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA Cancer Journal for Clinicians 2009 59 4 225 249
2. Bristow R. E., Puri I., Chi D. S., Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecologic Oncology 2009 112 1 265 274
3. Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S., Copeland L. J., Walker J. L., Burger R. A., Mackey D., Intraperitoneal cisplatin and paclitaxel in ovarian cancer The New England Journal of Medicine 2006 354 1 34 43 (Pubitemid 43048949)
4. Ozols R. F., Bundy B. N., Greer B. E., Fowler J. M., Clarke-Pearson D., Burger R. A., Mannel R. S., DeGeest K., Hartenbach E. M., Baergen R., Mackey D., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study Journal of Clinical Oncology 2003 21 17 3194 3200 (Pubitemid 46606249)
5. Shih I. M., Kurman R. J., Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis American Journal of Pathology 2004 164 5 1511 1518 (Pubitemid 38529752)
6. Risch H. A., McLaughlin J. R., Cole D. E. C., Rosen B., Bradley L., Fan I., Tang J., Li S., Zhang S., Shaw P. A., Narod S. A., Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada Journal of the National Cancer Institute 2006 98 23 1694 1706 (Pubitemid 44942707)
7. Yu Y., Luo R., Lu Z., Balch W. E., Der C., Hall A., Biochemistry and biology of ARHI (DIRAS3, an impronted tumor suppressor gene whose expression is lost in ovarian and breast cancers Methods in Enzymology: Regulators and Effectors of Small GTPases: Ras Family. 2006 407 455 467
8. Bali A., O'Brien P. M., Edwards L. S., Sutherland R. L., Hacker N. F., Henshall S. M., Cyclin D1, p53, and p21 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer Clinical Cancer Research 2004 10 15 5168 5177 (Pubitemid 39099792)
9. Buchynska L. G., Nesina I. P., Yurchenko N. P., Bilyk O. O., Grinkevych V. N., Svintitsky V. S., Expression of p53, p21, p16 and Ki-67 proteins in serous ovarian tumors Experimental Oncology 2007 29 1 49 53
10. Rosen D. G., Yang G., Cai K. Q., Bast R. C., Gershenson D. M., Silva E. G., Liu J., Subcellular localization of p27 expression predicts poor prognosis in human ovarian cancer Clinical Cancer Research 2005 11 2 632 637 (Pubitemid 40116889)
11. Quinn J. E., Carser J. E., James C. R., Kennedy R. D., Harkin D. P., BRCA1 and implications for response to chemotherapy in ovarian cancer Gynecologic Oncology 2009 113 1 134 142
12. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
13. Shibuya M., Claesson-Welsh L., Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Experimental Cell Research 2006 312 5 549 560 (Pubitemid 43290332)
14. Evans C., Dalgleish A. G., Kumar D., Review article: immune suppression and colorectal cancer Alimentary Pharmacology and Therapeutics 2006 24 8 1163 1177 (Pubitemid 44427504)
15. Barnett B., Kryczek I., Cheng P., Zou W., Curiel T. J., Regulatory T cells in ovarian cancer: biology and therapeutic potential American Journal of Reproductive Immunology 2005 54 6 369 377 (Pubitemid 41748714)
16. Kim R., Emi M., Tanabe K., Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity Immunology 2006 119 2 254 264 (Pubitemid 44401644)
17. Srivastava P. K., Old L. J., Individually distinct transplantation antigens of chemically induced mouse tumors Trends in Immunology 1988 9 112 84 88
18. Mathieu M. G., Miles A. K., Li G., McArdle S. E. B., Rees R. C., Cancer/testis antigens for therapeutic use Journal of the Balkan Union of Oncology 2009 14 1 S97 S102
19. Chu C. S., Kim S. H., Jun C. H., Coukos G., Immunotherapy opportunities in ovarian cancer Expert Review of Anticancer Therapy 2008 8 2 243 257 (Pubitemid 351385915)
20. Hellstrom K. E., Hellstrom I., Brown J. P., Human tumor-associated antigens identified by monoclonal antibodies Springer Seminars in Immunopathology 1982 5 2 127 146 (Pubitemid 13241291)
21. Renkvist N., Castelli C., Robbins P. F., Parmiani G., A listing of human tumor antigens recognized by T cells Cancer Immunology, Immunotherapy 2001 50 1 3 15 (Pubitemid 32250041)
22. Nair S. K., Bockzowski D., Morse M., Cumming I. R., Lyerly H. K., Gilboa E., Design and testing of peptide-based cytotoxic T cell mediated immunotherapeutics to treat infectious diseases and cancer Nature Biotechnology 1998 16 364 369
23. Banchereau J., Steinman R. M., Dendritic cells and the control of immunity Nature 1998 392 6673 245 252 (Pubitemid 28155090)
24. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P., McKenzie S., Yin S., Bast R. C., Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Research 1990 50 13 4087 4091 (Pubitemid 20225635)
25. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989 244 4905 707 712 (Pubitemid 19147683)
26. Wang Y., Kristensen G. B., Helland A., Nesland J. M., Borrensen-Dale A. L., Holm R., Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas American Journal of Clinical Pathology 2005 124 3 392 401 (Pubitemid 41232925)
27. Camilleri-Brot S., Hardy-Bessard A. C., Le Tourneau A., Paraiso D., Levrel O., Leduc B., Bain S., Orfeuvre H., Audouin J., Pujade-Lauraine E., HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group Annals of Oncology 2004 15 1 104 112 (Pubitemid 38145531)
28. Pieretti M., Hopenhayn-Rich C., Khattar N. H., Cao Y., Huang B., Tucker T. C., Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival Cancer Investigation 2002 20 1 11 23 (Pubitemid 34151056)
29. Shahin M. S., Hughes J. H., Sood A. K., Buller R. E., The prognostic significance of p53 tumour suppressor gene alterations in ovarian carcinoma Cancer 2000 89 2006 2017
30. Piersma S. J., Jordanova E. S., van Poelgeest M. I. E., Kwappenberg K. M. C., Van Der Hulst J. M., Drijfhout J. W., Melief C. J. M., Kenter G. G., Fleuren G. J., Offringa R., Van Der Burg S. H., High number of intraepithelial CD8 + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer Cancer Research 2007 67 1 354 361 (Pubitemid 46142795)
31. Dunn G. P., Old L. J., Schreiber R. D., The three Es of cancer immunoediting Annual Review of Immunology 2004 22 329 360 (Pubitemid 38680426)
32. Kohrt H. E., Nouri N., Nowels K., Johnson D., Holmes S., Lee P. P., Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer PLoS Medicine 2005 2 9 0904 0919 (Pubitemid 41382925)
33. Klemi P. J., Pylkknen L., Kiilholma P., Kurvinen K., Joensuu H., p53 Protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma Cancer 1995 76 7 1201 1208
34. Hashiguchi Y., Tsuda H., Inoue T., Nishimura S., Suzuki T., Kawamura N., Alteration of cell cycle regulators correlates with survival in epithelian ovarian cancer patients Human Pathology 2004 35 2 165 175 (Pubitemid 38240898)
35. Wang L., Ma J., Liu F., Yu Q., Chu G., Perkins A. C., Li Y., Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance Gynecologic Oncology 2007 105 3 695 702 (Pubitemid 46734194)
36. Anderson M. J., Shafer-Weaver K., Greenberg N. M., Hurwitz M. A., Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer Journal of Immunology 2007 178 1268 1276 (Pubitemid 46154596)
37. Schmielau J., Finn O. J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients Cancer Research 2001 61 12 4756 4760 (Pubitemid 32691887)
38. Dougan M., Dranoff G., The immune response to tumors Current Protocols in Immunology 2009 85 20.11.1 20.11.4
39. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D. D., Carbone D. P., Paul W. E., Berzofskv J. A., NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway Nature Immunology 2000 1 6 515 520
40. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G., Belinson J., Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design Journal of Clinical Oncology 2004 22 15 3120 3125 (Pubitemid 41103725)
41. Whiteside T. L., Immune responses to malignancies Journal of Allergy and Clinical Immunology 2010 125 2, supplement S272 S283
42. Yakirevich E., Sabo E., Lavie O., Mazareb S., Spagnoli G. C., Resnick M. B., Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms Clinical Cancer Research 2003 9 17 6453 6460 (Pubitemid 38031833)
43. Hislop A. D., Taylor G. S., Sauce D., Rickinson A. B., Cellular responses to viral infection in humans: lessons from Epstein-Barr virus Annual Review of Immunology 2007 25 587 617 (Pubitemid 46697918)
44. Ji H., Houghton A. M., Mariani T. J., Perera S., Kim C. B., Padera R., Tonon G., McNamara K., Marconcini L. A., Hezel A., El-Bardeesy N., Bronson R. T., Sugarbaker D., Maser R. S., Shapiro S. D., Wong K. K., K-ras activation generates an inflammatory response in lung tumors Oncogene 2006 25 14 2105 2112
45. Saeland E., Van Vliet S. J., Bckstrm M., van Den Berg V. C. M., Geijtenbeek T. B. H., Meijer G. A., Van Kooyk Y., The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma Cancer Immunology, Immunotherapy 2007 56 8 1225 1236 (Pubitemid 46763937)
46. Zeng G., Aldridge M. E., Tian X., Seiler D., Zhang X., Jin Y., Rao J., Li W., Chen D., Langford M. P., Duggan C., Belldegrun A. S., Dubinett S. M., Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system Journal of Immunology 2006 177 6 3582 3589 (Pubitemid 44359889)
47. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population The Lancet 2000 356 9244 1795 1799
48. Roithmaier S., Haydon A. M., Loi S., Esmore D., Griffiths A., Bergin P., Williams T. J., Schwarz M. A., Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience Journal of Heart and Lung Transplantation 2007 26 8 845 849 (Pubitemid 47214568)
49. Badoual C., Hans S., Rodriguez J., Peyrard S., Klein C., Agueznay N. E. H., Mosseri V., Laccourreye O., Bruneval P., Fridman W. H., Brasnu D. F., Tartour E., Prognostic value of tumor-infiltrating CD4 + T-cell subpopulations in head and neck cancers Clinical Cancer Research 2006 12 2 465 472 (Pubitemid 43166137)
50. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., Itoh T., Ohbuchi T., Kondo S., Katoh H., Concurrent infiltration by CD8 + T cells and CD4 + T cells is a favourable prognostic factor in non-small-cell lung carcinoma British Journal of Cancer 2006 94 2 275 280 (Pubitemid 43151547)
51. Tomov M., Melichar B., Sedlkov I., teiner I., Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecologic Oncology 2008 108 2 415 420 (Pubitemid 351174290)
52. Linn Y. C., Hui K. M., Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia Leukemia and Lymphoma 2003 44 9 1457 1462 (Pubitemid 36833956)
53. Lu P. H., Negrin R. S., A novel population of expanded human CD3CD56 cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency Journal of Immunology 1994 153 4 1687 1696 (Pubitemid 24251113)
54. Leemhuis T., Wells S., Scheffold C., Edinger M., Negrin R. S., A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Biology of Blood and Marrow Transplantation 2005 11 3 181 187 (Pubitemid 40287916)
55. Zhang L., Conejo-Garcia J. R., Katsaros D., Gimotty P. A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. C., Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer The New England Journal of Medicine 2003 348 3 203 213 (Pubitemid 36077915)
56. Nesbeth Y. C., Martinez D. G., Toraya S., Scarlett U. K., Cubillos-Ruiz J. R., Rutkowski M. R., Conejo-Garcia J. R., CD4 + T cells elicit host immune responses to MHC class IIovarian cancer through CCL5 secretion and CD4 + 0-mediated licensing of dendritic cells Journal of Immunology 2010 184 10 5654 5662
57. Bamias A., Koutsoukou V., Terpos E., Tsiatas M. L., Liakos C., Tsitsilonis O., Rodolakis A., Voulgaris Z., Vlahos G., Papageorgiou T., Papatheodoridis G., Archimandritis A., Antsaklis A., Dimopoulos M. A., Correlation of NK T-like CD3 + CD56 + cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNF in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy Gynecologic Oncology 2008 108 2 421 427
58. Papamichail M., Perez S. A., Gritzapis A. D., Baxevanis C. N., Natural killer lymphocytes: biology, development, and function Cancer Immunology, Immunotherapy 2004 53 3 176 186 (Pubitemid 38328040)
59. Lim S. H., Newland A. C., Kelsey S., Bell A., Offerman E., Rist C., Gozzard D., Bareford D., Smith M. P., Goldstone A. H., Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemiaa phase II study Cancer Immunology Immunotherapy 1992 34 5 337 342
60. Meropol N. J., Barresi G. M., Fehniger T. A., Hitt J., Franklin M., Caligiuri M. A., Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing Cancer Immunology Immunotherapy 1998 46 6 318 326 (Pubitemid 28410578)
61. Soiffer R. J., Murray C., Gonin R., Ritz J., Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation Blood 1994 84 3 964 971 (Pubitemid 24223898)
62. Rosenberg S. A., Lotze M. T., Muul L. M., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer The New England Journal of Medicine 1985 313 23 1485 1492 (Pubitemid 16212345)
63. Gubbels J. A. A., Felder M., Horibata S., Belisle J. A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J. P., Patankar M. S., MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells Molecular Cancer 2010 9, article 11
64. Carlsten M., Bjrkstrm N. K., Norell H., Bryceson Y., Van Hall T., Baumann B. C., Hanson M., Schedvins K., Kiessling R., Ljunggren H. G., Malmberg K. J., DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells Cancer Research 2007 67 3 1317 1325
65. Webb T. J., Giuntoli R. L., Rogers O., Schneck J., Oelke M., Ascites specific inhibition of CDId-mediated activation of natural Killer T Cells Clinical Cancer Research 2008 14 23 7652 7658
66. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T., Fujii S., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3360 3365 (Pubitemid 46364164)
67. Maddaluno L., Verbrugge S. E., Martinoli C., Matteoli G., Chiavelli A., Zeng Y., Williams E. D., Rescigno M., Cavallaro U., The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells Journal of Experimental Medicine 2009 206 3 623 635
68. Zecchini S., Bianchi M., Colombo N., Fasani R., Goisis G., Casadio C., Viale G., Liu J., Herlyn M., Godwin A. K., Nuciforo P. G., Cavallaro U., The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium Cancer Research 2008 68 4 1110 1118 (Pubitemid 351272229)
69. Sato E., Olson S. H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A. A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y. T., Ohtani H., Old L. J., Odunsi K., Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 + /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18538 18543 (Pubitemid 43011261)
70. Kryczek I., Liu R., Wang G., Wu KE., Shu X., Szeliga W., Vatan L., Finlayson E., Huang E., Simeone D., Redman B., Welling T. H., Chang A., Zou W., FOXP3 defines regulatory t cells in human tumor and autoimmune disease Cancer Research 2009 69 9 3995 4000
71. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 (Pubitemid 32691889)
72. Bamias A., Tsiatas M. L., Kafantari E., Liakou C., Rodolakis A., Voulgaris Z., Vlahos G., Papageorgiou T., Tsitsilonis O., Bamia C., Papatheodoridis G., Politi EK., Archimandritis A., Antsaklis A., Dimopoulos M. A., Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3 + CD56 + cells with platinum resistance Gynecologic Oncology 2007 106 1 75 81 (Pubitemid 46898574)
73. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949 (Pubitemid 39273735)
74. Wolf D., Wolf A. M., Rumpold H., Fiegl H., Zeimet A. G., Muller-Holzner E., Deibl M., Gastl G., Gunsilius E., Marth C., The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer Clinical Cancer Research 2005 11 23 8326 8331 (Pubitemid 41746944)
75. Lutsiak M. E. C., Semnani R. T., De Pascalis R., Kashmiri S. V. S., Schlom J., Sabzevari H., Inhibition of CD4 + 25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005 105 7 2862 2868 (Pubitemid 40446280)
76. Perez S. A., Karamouzis M. V., Skarlos D. V., Ardavanis A., Sotiriadou N. N., Iliopoulou E. G., Salagianni M. L., Orphanos G., Baxevanis C. N., Rigatos G., Papamichail M., CD4 + CD25 + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients Clinical Cancer Research 2007 13 9 2714 2721 (Pubitemid 46788040)
77. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 (Pubitemid 32691889)
78. Ercolini A. M., Ladle B. H., Manning E. A., Pfannenstiel L. W., Armstrong T. D., Machiels J. P. H., Bieler J. G., Emens L. A., Reilly R. T., Jaffee E. M., Recruitment of latent pools of high-avidity CD8 + T cells to the antitumor immune response Journal of Experimental Medicine 2005 201 10 1591 1602 (Pubitemid 40723662)
79. Leveque L., Deknuydt F., Bioley G., Old L. J., Matsuzaki J., Odunsi K., Ayyoub M., Valmori D., Interleukin 2-mediated conversion of ovarian cancer-associated CD4 + regulatory T cells into proinflammatory interleukin 17-producing helper T cells Journal of Immunotherapy 2009 32 2 101 108
80. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T. H., Chang A., Coukos G., Liu R., Zou W., Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments Blood 2009 114 6 1141 1149
81. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., Curiel T., Lange A., Zou W., Plasmacytoid dendritic cells induce CD8 + regulatory T cells in human ovarian carcinoma Cancer Research 2005 65 12 5020 5026 (Pubitemid 40827308)
82. Klimp A. H., Hollema H., Kempinga C., van der Zee A. G. J., De Vries E. G. E., Daemen T., Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages Cancer Research 2001 61 19 7305 7309 (Pubitemid 32946529)
83. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., Lackner A., Alvarez X., Ochoa A., Chen L., Zou W., B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma Journal of Experimental Medicine 2006 203 4 871 881
84. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends in Immunology 2002 23 11 549 555 (Pubitemid 35223554)
85. Wyckoff J., Wang W., Lin E. Y., Wang Y., Pixley F., Stanley E. R., Graf T., Pollard J. W., Segall J., Condeelis J., A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors Cancer Research 2004 64 19 7022 7029 (Pubitemid 39331012)
86. Solans-Laqu R., Prez-Bocanegra C., Salud-Salvia A., Fonollosa-Pl V., Rodrigo M. J., Armadans L., Simen-Aznar C. P., Vilardell-Tarres M., Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes Lupus 2004 13 3 159 164 (Pubitemid 38478641)
87. Sommer C., Weishaupt A., Brinkhoff J., Biko L., Wessig C., Gold R., Toyka K. V., Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin The Lancet 2005 365 9468 1406 1411 (Pubitemid 40523735)
88. Balint K., Conejo-Garcia J. R., Buckanovich R., Coukos G., Role of vascular leukocytes in ovarian cancer neovascularization Advances in Experimental Medicine and Biology 2008 622 273 280
89. Emens L. A., Jaffee E. M., Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Research 2005 65 18 8059 8064 (Pubitemid 41330564)
90. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F., CD4 + CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative European Journal of Immunology 2004 34 2 336 344 (Pubitemid 39255944)
91. Suzuki E., Kapoor V., Jassar A. S., Kaiser L. R., Albelda S. M., Gemcitabine selectively eliminates splenic Gr-1 + /CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clinical Cancer Research 2005 11 18 6713 6721 (Pubitemid 41339014)
92. Correale P., Cusi M. G., Del Vecchio M. T., Aquino A., Prete S., Tsang K. Y., Micheli L., Nencini C., La Placa M., Montagnani F., Terrosi C., Caraglia M., Formica V., Giorgi G., Bonmassar E., Francini G., Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro Journal of Immunology 2005 175 2 820 828 (Pubitemid 41094964)
93. Correale P., Cusi M. G., Tsang K. Y., Del Vecchio M. T., Marsili S., La Placa M., Intrivici C., Aquino A., Micheli L., Nencini C., Ferrari F., Giorgi G., Bonmassar E., Francini G., Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients Journal of Clinical Oncology 2005 23 35 8950 8958 (Pubitemid 46211480)
94. Chen R., Alvero A. B., Silasi D. A., Steffensen K. D., Mor G., Cancers take their Toll-The function and regulation of Toll-like receptors in cancer cells Oncogene 2008 27 2 225 233
95. Romagnani S., The Th1/Th2 paradigm Immunology Today 1997 18 6 263 266 (Pubitemid 27261442)
96. Pisa P., Halapi E., Pisa E. K., Gerdin E., Hising C., Bucht A., Gerdin B., Kiessling R., Selective expression of interleukin 10, interferon, and granulocyte- macrophage colony-stimulating factor in ovarian cancer biopsies Proceedings of the National Academy of Sciences of the United States of America 1992 89 16 7708 7712
97. Chen L. L., Ye F., L W. G., Yu Y., Chen H. Z., Xie X., Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma Journal of Obstetrics and Gynaecology Research 2009 35 2 212 218
98. Zeimet A. G., Widschwendter M., Knabbe C., Fuchs D., Herold M., Mller-Holzner E., Daxenbichler G., Offner F. A., Dapunt O., Marth C., Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer Journal of Clinical Oncology 1998 16 5 1861 1868 (Pubitemid 28234733)
99. Chen J. J.W., Yao P. -L., Yuan A., Hong T. -M., Shun C. -T., Kuo M. -L., Lee Y. -C., Yang P. -C., Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer Clinical Cancer Research 2003 9 2 729 737 (Pubitemid 36182607)
100. Asschert J. G.W., Vellenga E., Hollema H., van der Zee A. G. J., de Vries E. G.E., Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 (IL-1 ), interleukin-11 (IL-11) and tumour necrosis factor- (TNF- ) in p53-characterised human ovarian carcinomas European Journal of Cancer 1997 33 13 2246 2251
101. Milliken D., Scotton C., Raju S., Balkwill F., Wilson J., Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites Clinical Cancer Research 2002 8 4 1108 1114 (Pubitemid 35177363)
102. Setoguchi R., Hori S., Takahashi T., Sakaguchi S., Homeostatic maintenance of natural Foxp3 + CD25 + CD4 + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization Journal of Experimental Medicine 2005 201 5 723 735 (Pubitemid 40395118)
103. Lenardo M. J., Boehme S., Chen L., Combadiere B., Fisher G., Freedman M., McFarland H., Pelfrey C., Zheng L., Automne feedback death and the regulation of mature T lymphocyte antigen responses International Reviews of Immunology 1996 13 2 115 134 (Pubitemid 126837088)
104. Kikuchi T., Akasaki Y., Abe T., Fukuda T., Saotome H., Ryan J. L., Kufe D. W., Ohno T., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12 Journal of Immunotherapy 2004 27 6 452 459 (Pubitemid 39447353)
105. Dou J., Wang Y., Wang J., Zhao F., Li Y., Cao M., Hu W., Hu K., He X. F., Chu L., Jiang C., Gu N., Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model Immunobiology 2009 214 6 483 492
106. Nakano H., Kishida T., Asada H., Shin-Ya M., Shinomiya T., Imanishi J., Shimada T., Nakai S., Takeuchi M., Hisa Y., Mazda O., Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma Journal of Gene Medicine 2006 8 1 90 99 (Pubitemid 43169385)
107. Kusuda T., Shigemasa K., Arihiro K., Fujii T., Nagai N., Ohama K., Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer Oncology Reports 2005 13 6 1153 1158
108. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., Kainz C., Serum evaluation of interleukin 6 in ovarian cancer patients Gynecologic Oncology 1997 66 1 27 30 (Pubitemid 27329303)
109. Scambia G., Testa U., Panici P. B., Martucci R., Foti E., Petrini M., Amoroso M., Masciullo V., Peschle C., Mancuso S., Interleukin-6 serum levels in patients with gynecological tumors International Journal of Cancer 1994 57 3 318 323 (Pubitemid 24168603)
110. Marth C., Zeimet A. G., Herold M., Brumm C., Windbichler G., Mller-Holzner E., Offner F., Feichtinger H., Zwierzina H., Daxenbichler G., Different effects of interferons, interleukin-1 and tumor necrosis factor- in normal (OSE) and malignant human ovarian epithelial cells International Journal of Cancer 1996 67 6 826 830 (Pubitemid 26348812)
111. Chen Z., Fadiel A., Feng Y., Ohtani K., Rutherford T., Naftolin F., Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1 and epidermal growth factor Cancer 2001 92 12 3068 3075 (Pubitemid 33136203)
112. Rowley J., Monie A., Hung C. -F., Wu T. -C., Inhibition of tumor growth by NK1.1 + cells and CD8 + T cells activated by IL-15 through receptor /common signaling in trans Journal of Immunology 2008 181 12 8237 8247
113. Kriegel M. A., Li M. O., Sanjabi S., Wan Y. Y., Flavell R. A., Transforming growth factor- : recent advances on its role in immune tolerance Current Rheumatology Reports 2006 8 2 138 144 (Pubitemid 44623982)
114. Rodriguez G. C., Haisley C., Hurteau J., Moser T. L., Whitaker R., Bast R. C., Stack M. S., Regulation of invasion of epithelial ovarian cancer by transforming growth factor- Gynecologic Oncology 2001 80 2 245 253 (Pubitemid 32158466)
115. Pepper M. S., Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity Cytokine and Growth Factor Reviews 1997 8 1 21 43 (Pubitemid 27214687)
116. Wu S., Boyer C. M., Whitaker R. S., Berchuck A., Wiener J. R., Weinberg J. B., Bast R. C., Tumor necrosis factor as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor expression Cancer Research 1993 53 8 1939 1944 (Pubitemid 23127128)
117. Naylor M. S., Stamp G. W. H., Foulkes W. D., Eccles D., Balkwill F. R., Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression Journal of Clinical Investigation 1993 91 5 2194 2206 (Pubitemid 23141496)
118. Kulbe H., Thompson R., Wilson J. L., The inflammatory cytokine tumour necrosis factor-alpha generates an autocrine tumor promoting network in epithelial ovarian cancer cells Cancer Research 2007 67 585 592 (Pubitemid 46192196)
119. Goldstein I., Ben-Horin S., Koltakov A., Chermoshnuk H., Polevoy V., Berkun Y., Amariglio N., Bank I., 1 1 integrin+ and regulatory Foxp3 + T cells constitute two functionally distinct human CD4 + T cell subsets oppositely modulated by TNF blockade Journal of Immunology 2007 178 1 201 210
120. Milliken D., Scotton C., Raju S., Balkwill F., Wilson J., Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites Clinical Cancer Research 2002 8 4 1108 1114 (Pubitemid 35177363)
121. Negus R. P. M., Stamp G. W. H., Hadley J., Balkwill F. R., Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines American Journal of Pathology 1997 150 5 1723 1734 (Pubitemid 27193819)
122. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., Curiel T., Lange A., Zou W., Plasmacytoid dendritic cells induce CD8 + regulatory T cells
123. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity International Journal of Cancer 2010 127 4 759 767
124. Duluc D., Corvaisier M., Blanchard S., Catala L., Descamps P., Gamelin E., Ponsoda S., Delneste Y., Hebbar M., Jeannin P., Interferon- reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages International Journal of Cancer 2009 125 2 367 373
125. Samsami Dehaghani A., Shahriary K., Kashef M. A., Naeimi S., Fattahi M. J., Mojtahedi Z., Ghaderi A., Interleukin-18 gene promoter and serum level in women with ovarian cancer Molecular Biology Reports 2009 36 8 2393 2397
126. Jaszczyska-Nowinka K., Markowska A., New cytokine: stromal derived factor-1 European Journal of Gynaecological Oncology 2009 30 2 124 127
127. Rudlowski C., Pickart A.-K., Fuhljahn C., Friepoertner T., Schlehe B., Biesterfeld S., Schroeder W., Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up International Journal of Gynecological Cancer 2006 16 supplement 1 183 189
128. Ohm J. E., Gabrilovich D. I., Sempowski G. D., Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynaecological tumor cells Blood 2003 101 4878 4886
129. Dikov M. M., Ohm J. E., Ray N., Tchekneva E. E., Burlison J., Moghanaki D., Nadaf S., Carbone D. P., Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation Journal of Immunology 2005 174 1 215 222 (Pubitemid 40007407)
130. Lissoni P., Malugani F., Bonfanti A., Bucovec R., Secondino S., Brivio F., Ferrari-Bravo A., Ferrante R., Vigore L., Rovelli F., Mandala M., Vivian S., Fumagalli L., Gardani G. S., Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 Journal of Biological Regulators and Homeostatic Agents 2001 15 2 140 144 (Pubitemid 32717550)
131. Trinh X. B., Tjalma W. A. A., Vermeulen P. B., Van Den Eynden G., Van Der Auwera I., Van Laere S. J., Helleman J., Berns E. M. J. J., Dirix L. Y., Van Dam P. A., The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer British Journal of Cancer 2009 100 6 971 978
132. Costa L. J., Drabkin H. A., Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies Oncologist 2007 12 12 1404 1415
133. Gaumann A., Schlitt H. J., Geissler E. K., Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin Transplant International 2008 21 3 207 217 (Pubitemid 351216959)
134. Suzuki H., Onishi H., Wada J., Yamasaki A., Tanaka H., Nakano K., Morisaki T., Katano M., VEGFR2 is selectively expressed by FOXP 3high CD4 + Treg European Journal of Immunology 2010 40 1 197 203
135. Chen C. A., Cheng W. F., Lee C. N., Chen T. M., Kung C. C. S., Hsieh F. J., Hsieh C. Y., Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival Gynecologic Oncology 1999 74 2 235 240
136. Secord A. A., Sayer R., Snyder S. A., Broadwater G., Rodriguez G. C., Berchuck A., Blackwell K., The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer Gynecologic Oncology 2004 94 1 74 79 (Pubitemid 38950501)
137. Vysotskii M. M., Digaeva M. A., Kushlinskii N. E., Abbasova S. G., Laktionov K. P., Ermilova V. D., Bakhoeva K. A., Kryuk YU. V., Manukhin I. B., Serum sFas, Leptin, and VEGF in patients with ovarian cancer and benign tumors Bulletin of Experimental Biology and Medicine 2009 148 5 810 814
138. Schultes B. C., Nicodemus C. F., Using antibodies in tumour immunotherapy Expert Opinion on Biological Therapy 2004 4 8 1265 1284 (Pubitemid 39005733)
139. Niarchos D. K., Perez S. A., Papamichail M., Characterization of a novel cell penetrating peptide derived from Bag-1 protein Peptides 2006 27 11 2661 2669 (Pubitemid 44584403)
140. Sharkey R. M., Goldenberg D. M., Targeted therapy of cancer: new prospects for antibodies and immunoconjugates Ca-A Cancer Journal for Clinicians 2006 56 4 226 243 (Pubitemid 44175051)
141. Menendez J. A., Mehmi I., Lupu R., Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression Journal of Clinical Oncology 2006 24 23 3735 3746 (Pubitemid 46622312)
142. Berek J. S., Dorigo O., Schultes B., Nicodemus C., Specific keynote: immunological therapy for ovarian cancer Gynecologic Oncology 2003 88 1 S105 S109
143. del Carmen M. G., Rizvi I., Chang Y., Synergism of epidermal growth factor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo Journal of the National Cancer Institute 2005 97 1516 1524 (Pubitemid 41631951)
144. Aghajanian C., The role of bevacizumab in ovarian canceran evolving story Gynecologic Oncology 2006 102 2 131 133 (Pubitemid 44041664)
145. Monk B. J., Han E., Josephs-Cowan C. A., Pugmire G., Burger R. A., Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecologic Oncology 2006 102 2 140 144 (Pubitemid 44056265)
146. Burger R. A., Brady M. F., Bookman M. A., Phase III trial of bevacizumab (BEV) in the primary treatment of advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal Cancer (PPC), or Fallopian Tube Cancer (FTC): a Gynecologic Oncology Group study Journal of Clinical Oncology 2010 28, Supplement 15 5s
147. Cannistra S. A., Matulonis U. A., Penson R. T., Hambleton J., Dupont J., Mackey H., Douglas J., Burger R. A., Armstrong D., Wenham R., McGuire W., Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer Journal of Clinical Oncology 2007 25 33 5180 5186 (Pubitemid 350232248)
148. Perren T., Swart A. M., Pfisterer J., ICON7: a phase III randomized Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, verus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) Proceedings of the 35th ESMO Congress October 2010. LBA4
149. Mbus V. J., Baum R. P., Bolle M., Kreienberg R., Noujaim A. A., Schultes B. C., Nicodemus C. F., Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer American Journal of Obstetrics and Gynecology 2003 189 1 28 36 (Pubitemid 36886520)
150. Berek J. S., Taylor P. T., Gordon A., Cunningham M. J., Finkler N., Orr Jr. J., Rivkin S., Schultes B. C., Whiteside T. L., Nicodemus C. F., Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer Journal of Clinical Oncology 2004 22 17 3507 3516 (Pubitemid 41103657)
151. Gordon M. S., Matei D., Aghajanian C., Matulonis U. A., Brewer M., Fleming G. F., Hainsworth J. D., Garcia A. A., Pegram M. D., Schilder R. J., Cohn D. E., Roman L., Derynck M. K., Ng K., Lyons B., Allison D. E., Eberhard D. A., Pham T. Q., Dere R. C., Karlan B. Y., Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status Journal of Clinical Oncology 2006 24 26 4324 4332 (Pubitemid 46630791)
152. Konner J., Schilder R. J., DeRosa F. A., Gerst S. R., Tew W. P., Sabbatini P. J., Hensley M. L., Spriggs D. R., Aghajanian C. A., A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer Gynecologic Oncology 2008 110 2 140 145
153. Seiden M. V., Burris H. A., Matulonis U., Hall J. B., Armstrong D. K., Speyer J., Weber J. D.A., Muggia F., A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies Gynecologic Oncology 2007 104 3 727 731
154. Burger R. A., Experience with bevacizumab in the management of epithelial ovarian cancer Journal of Clinical Oncology 2007 25 20 2902 2908 (Pubitemid 47123154)
155. Hu L., Hofmann J., Holash J., Yancopoulos G. D., Sood A. K., Jaffe R. B., Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model Clinical Cancer Research 2005 11 19 6966 6971 (Pubitemid 41428755)
156. Li B., Lalani A. S., Harding T. C., Luan BO., Koprivnikar K., Guang H. T., Prell R., VanRoey M. J., Simmons A. D., Jooss K., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy Clinical Cancer Research 2006 12 22 6808 6816 (Pubitemid 44876851)
157. Schmeler K. M., Vadhan-Raj S., Ramirez P. T., Apte S. M., Cohen L., Bassett R. L., Iyer R. B., Wolf J. K., Levenback C. L., Gershenson D. M., Freedman R. S., A phase II study of GM-CSF and rIFN- 1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer Gynecologic Oncology 2009 113 2 210 215
158. Windbichler G. H., Hausmaninger H., Stummvoll W., Graf A. H., Kainz C., Lahodny J., Denison U., Mller-Holzner E., Marth C., Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial British Journal of Cancer 2000 82 6 1138 1144 (Pubitemid 30128869)
159. Hall G. D., Brown J. M., Coleman R. E., Stead M., Metcalf K. S., Peel K. R., Poole C., Crawford M., Hancock B., Selby P. J., Perren T. J., Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study British Journal of Cancer 2004 91 4 621 626 (Pubitemid 39141614)
160. Alberts D. S., Marth C., Alvarez R. D., Johnson G., Bidzinski M., Kardatzke D. R., Bradford W. Z., Loutit J., Kirn D. H., Clouser M. C., Markman M., Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival Gynecologic Oncology 2008 109 2 174 181
161. Ribas A., Butterfield L. H., Glaspy J. A., Economou J. S., Current developments in cancer vaccines and cellular immunotherapy Journal of Clinical Oncology 2003 21 12 2415 2432 (Pubitemid 46621880)
162. Wagner U., Khler S., Reinartz S., Giffels P., Huober J., Renke K., Schlebusch H., Biersack H. -J., Mbus V., Kreienberg R., Bauknecht T., Krebs D., Wallwiener D., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment Clinical Cancer Research 2001 7 5 1154 1162 (Pubitemid 32708665)
163. Schuurhuis D. H., Van Montfoort N., Ioan-Facsinay A., Jiawan R., Camps M., Nouta J., Melief C. J. M., Verbeek J. S., Ossendorp F., Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine Journal of Immunology 2006 176 8 4573 4580
164. Fricke I., Gabrilovich D. I., Dendritic cells and tumor microenvironment: a dangerous liaison Immunological Investigations 2006 35 3-4 459 483 (Pubitemid 44266783)
165. Hodge J. W., Tsang K. Y., Poole D. J., Schlom J., General keynote: vaccine strategies for the therapy of ovarian cancer Gynecologic Oncology 2003 88 1 S97 S104. Discussion pp. S103S110
166. Slingluff C. L., Speiser D. E., Progress and controversies in developing cancer vaccines Journal of Translational Medicine 2005 3, article no. 18
167. Dudley M. E., Rosenberg S. A., Adoptive-cell-transfer therapy for the treatment of patients with cancer Nature Reviews Cancer 2003 3 9 666 675 (Pubitemid 37328821)
168. de Gramont A., Gangji D., Louvet C., Garcia M. L., Tardy D., Romet-Lemonne J. L., Adoptive immunotherapy of ovarian carcinoma Gynecologic Oncology 2002 86 1 102 103 (Pubitemid 34757060)
169. Kershaw M. H., Westwood J. A., Parker L. L., Wang G., Eshhar Z., Mavroukakis S. A., White D. E., Wunderlich J. R., Canevari S., Rogers-Freezer L., Chen C. C., Yang J. C., Rosenberg S. A., Hwu P., A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clinical Cancer Research 2006 12 20 6106 6115 (Pubitemid 44703776)
170. Ritchie D., Mileshkin L., Wall D., Bartholeyns J., Thompson M., Coverdale J., Lau E., Wong J., Eu P., Hicks R. J., Prince H. M., In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma Cancer Immunology, Immunotherapy 2007 56 2 155 163 (Pubitemid 44833090)
171. Barber A., Rynda A., Sentman C. L., Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment Journal of Immunology 2009 183 11 6939 6947
172. De Cesare M., Sfondrini L., Campiglio M., Sommariva M., Bianchi F., Perego P., Van Rooijen N., Supino R., Rumio C., Zunino F., Pratesi G., Tagliabue E., Balsari A., Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN Journal of Immunotherapy 2010 33 1 8 15
173. Curiel T. J., Barnett B., Krysczek I., Cheng P., Zou W., Regulatory T cells in ovarian cancer: biology and therapeutic potential Cancer Immunity 2006 6 20 21